Your session is about to expire
← Back to Search
Continuous Glucose Monitor
Continuous Glucose Monitoring for Diabetes in Hemodialysis Patients (DEXCOM-HD Trial)
N/A
Waitlist Available
Led By Connie Rhee, MD, MSc
Research Sponsored by University of California, Irvine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 to 5 days
Awards & highlights
DEXCOM-HD Trial Summary
This trial is testing whether a continuous glucose monitor (CGM) is accurate compared to standard blood sugar tests in people with diabetes who are on dialysis.
Who is the study for?
This trial is for adults over 18 who are on hemodialysis due to kidney issues and also have diabetes. They must be patients at the University of California Irvine Medical Center with an expected hospital stay of at least 48 hours and can give informed consent.Check my eligibility
What is being tested?
The study tests how well the Dexcom G6 Continuous Glucose Monitor tracks blood sugar levels compared to standard fingerstick or venous blood glucose measurements in hemodialysis patients with diabetes.See study design
What are the potential side effects?
While not explicitly stated, potential side effects may include skin irritation from the CGM device adhesive, discomfort during sensor insertion, and possible inaccuracies leading to mismanagement of glucose levels.
DEXCOM-HD Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 to 5 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 to 5 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Blood glucose measurement
Secondary outcome measures
Hypoglycemia events
DEXCOM-HD Trial Design
1Treatment groups
Experimental Treatment
Group I: Dexcom G6 Continuous Glucose MonitorExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexcom G6 Continuous Glucose Monitor
2021
N/A
~30
Find a Location
Who is running the clinical trial?
University of California, IrvineLead Sponsor
543 Previous Clinical Trials
1,922,971 Total Patients Enrolled
DexCom, Inc.Industry Sponsor
137 Previous Clinical Trials
29,820 Total Patients Enrolled
Connie Rhee, MD, MScPrincipal InvestigatorFaculty
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Dexcom G6 Continuous Glucose Monitor
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is the enrollment phase for this experiment ongoing at present?
"According to clinicaltrials.gov, the trial is no longer recruiting patients as of June 9th 2023. Originally posted on March 1st 2020, it has now concluded its search for volunteers. However, there are currently 218 other studies actively enrolling participants."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger